Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Femasys Inc (FEMY)

Femasys Inc (FEMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Femasys Regains Compliance with Nasdaq Listing Requirements GlobeNewswire - Wed Jun 24, 8:00AM CDT

ATLANTA, June 24, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective...

FEMY : 3.80 (+5.56%)
Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter GlobeNewswire - Wed May 13, 8:00AM CDT

ATLANTA, May 13, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective...

FEMY : 3.80 (+5.56%)
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update GlobeNewswire - Fri May 8, 3:05PM CDT

ATLANTA, May 08, 2026 (GLOBE NEWSWIRE) --   Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective...

FEMY : 3.80 (+5.56%)
Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete GlobeNewswire - Tue May 5, 8:00AM CDT

-- Integrated sperm preparation and intratubal insemination drive earlier intervention and streamlined, in-office care within routine OB/GYN practice -- ATLANTA, May 05, 2026 (GLOBE NEWSWIRE) --...

FEMY : 3.80 (+5.56%)
Femasys Launches FemaSeed® Complete for OB/GYNs at ACOG 2026 GlobeNewswire - Wed Apr 22, 8:00AM CDT

ATLANTA, April 22, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective...

FEMY : 3.80 (+5.56%)
Femasys Drives International Growth with Israeli Market Entry for Fertility Portfolio GlobeNewswire - Thu Apr 16, 8:00AM CDT

-- Partnership with AMI Technologies Positions FemaSeed ® as a First-Line Infertility Treatment in Israel, Expanding Market Access to Innovative Fertility Solutions --  ATLANTA, April 16, 2026...

FEMY : 3.80 (+5.56%)
Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth GlobeNewswire - Wed Apr 1, 8:00AM CDT

ATLANTA, April 01, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective...

FEMY : 3.80 (+5.56%)
Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update GlobeNewswire - Tue Mar 31, 3:05PM CDT

ATLANTA, March 31, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective...

FEMY : 3.80 (+5.56%)
Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors GlobeNewswire - Wed Mar 18, 8:00AM CDT

ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective...

FEMY : 3.80 (+5.56%)
Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment GlobeNewswire - Tue Mar 10, 8:00AM CDT

-- Enrollment begins in the FDA-authorized FINALE pivotal trial evaluating FemBloc, a first-of-its-kind non-surgical permanent birth control, following positive clinical data -- ATLANTA, March 10,...

FEMY : 3.80 (+5.56%)

Barchart Exclusives

Nvidia and Broadcom Both Offer AI Exposure and Dividends. Barchart Data Helps Pick the Best Stock to Buy Now. Barchart - 1 hour ago
Nvidia and Broadcom both offer AI exposure and dividends, but the better stock depends on what investors value most. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.